ERBB2 and breast cancer: More recently, the advent of next-generation sequencing has facilitated the discovery of a spectrum of somatic HER2 gene mutations that serve as oncogenic drivers and can be therapeutically targeted.2,3 Several HER2-targeted therapies have been developed and approved for the treatment of HER2-positive (HER2+) breast cancer over the past three decades.